Disease relevance of RABGAP1

• PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer [1].

High impact information on RABGAP1

• A similar phenotype was observed when GAPCenA, a GTPase-activating protein of Rab6, was depleted from cells [2].
• Rab6A', through its interaction with p150(Glued) and GAPCenA, may thus participate in a pathway involved in the metaphase/anaphase transition [2].
• Immunofluorescence and cell fractionation experiments showed that GAPCenA is mainly cytosolic but that a minor pool is associated with the centrosome [3].
• Therefore, GAPCenA may be involved in the coordination of microtubule and Golgi dynamics during the cell cycle [3].
• In addition, Rab6A' interacts with two Rab6A partners, GAPCenA and "clone 1," but not with the kinesin-like protein Rabkinesin-6, a Golgi-associated Rab6A effector [4].

Biological context of RABGAP1

• Substrate specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein Tbc1d1 [5].

Other interactions of RABGAP1

• The human EVI5 protein carries a TBC domain indicative of Rab GTPase activating protein (GAP) activity, and an extensive coiled-coil motif in the C-terminal region [6].
• Identification of Rab GTPase-activating protein-like protein (RabGAPLP) as a novel Alix/AIP1-interacting protein [7].

Analytical, diagnostic and therapeutic context of RABGAP1

• Primary sequence analysis indicates that GAPCenA displays similarities, within a central 200 amino acids domain, to both the yeast Rab GTPase activating proteins (GAPs) and to the spindle checkpoint proteins Saccharomyces cerevisiae Bub2p and Schizosaccharomyces pombe Cdc16p [3].

References